Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS

NCT05703607 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05703607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05703607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
January 25, 2023
Completion date
September 23, 2025
Enrollment
484 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster infection, human, shingles